問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Pediatrics

更新時間：2023-09-19

謝旻玲
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

6Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

謝旻玲

List

7Cases

2018-10-01 - 2026-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2019-05-03 - 2023-12-28

Phase III

Completed
A Multicenter Study to Evaluate Long-term Safety and Tolerability of Open Label Sacubitril/Valsartan in Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed Study CLCZ696B2319

  • Condition/Disease

    Heart failure

  • Test Drug

    健安心/Entresto (LCZ696)

Participate Sites
3Sites

Not yet recruiting1Sites

Recruiting2Sites

2025-11-14 - 2030-06-28

Phase III

Active
A multicenter, randomized, double-blind, placebo-controlled, Phase 3 study to investigate the efficacy, safety, and PK/ PD of finerenone, in addition to standard-of-care, in pediatric patients, 6 months to < 18 years of age with heart failure (HF) and left ventricular systolic dysfunction (LVSD)

  • Condition/Disease

    Left Ventricular Systolic Dysfunction

  • Test Drug

    錠劑 錠劑 錠劑 懸浮液用顆粒劑 錠劑 懸液用顆粒劑

Participate Sites
6Sites

Recruiting6Sites

2026-02-20 - 2031-06-30

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2018-10-01 - 2025-12-31

Phase II

A Prospective, Multicenter, Open Label, Single Arm, Phase 2 Study to Investigate the Safety, Tolerability and Pharmacokinetics of Selexipag in Children With Pulmonary Arterial Hypertension

  • Condition/Disease

    Pulmonary Arterial Hypertension

  • Test Drug

    Selexipag

Participate Sites
2Sites

Recruiting1Sites

Terminated1Sites

2020-04-01 - 2028-02-29

Phase III

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Event-Driven, Group-Sequential Study With Open-Label Extension Period to Assess the Efficacy and Safety of Selexipag as Add-On Treatment to Standard of Care in Children Aged >=2 to <18 Years With Pulmonary Arterial Hypertension

  • Condition/Disease

    Pulmonary Arterial Hypertension

  • Test Drug

    Uptravi

Participate Sites
3Sites

Not yet recruiting1Sites

Recruiting1Sites

Terminated1Sites

2017-03-31 - 2022-07-01

Phase II/III

Multicenter, open-label, study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of LCZ696 followed by a 52-week randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril in pediatric patients from 1 month to < 18 years of age with heart failure due to systemic left ventricle systolic dysfunction.

  • Condition/Disease

    pediatric patients with heart failure due to systemic left ventricle systolic dysfunction.

  • Test Drug

    LCZ696

Participate Sites
3Sites

Recruiting3Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB